Healthcare Companies in the News for July 8 - Alliqua, Inc., Derma Sciences, MiMedx, Integra LifeSciences, Oculus Innovative

 Healthcare Companies in the News for July 8 - Alliqua, Inc., Derma Sciences,
               MiMedx, Integra LifeSciences, Oculus Innovative

PR Newswire

CORAL SPRINGS, Florida, July 8, 2013

CORAL SPRINGS, Florida, July 8, 2013 /PRNewswire/ -- issues market news updates for today's active
healthcare companies: Alliqua, Inc. (OTCQB: ALQA), Derma Sciences Inc.
(NASDAQ: DSCI), MiMedx Group, Inc. (NASDAQ: MDXG), Integra LifeSciences
Holdings Corporation (NASDAQ: IART) and Oculus Innovative Sciences, Inc.

Headline News Alert: Alliqua, Inc. (OTCQB:ALQA) today announced that it has
successfully met its financing goals, raising $3 million through the sale of
common stock and warrants over the past 3 months. A group of accredited
investors purchased the equity at $0.081 per share, coupled with a warrant to
purchase an additional share of common stock at $0.097 per share. The first
$1 million investment, as previously disclosed by the Company, took place
between April and May of 2013. The remaining $2 million was raised on June
28, 2013 and was led by group of Alliqua's management and board of directors,
including Jerome Zeldis, Dave Johnson, David Stefansky, Joseph Leone and
Kenneth Pearsen. Dr. Zeldis, who serves as the Chairman of the Board of
Alliqua, is the current chief medical officer of Celgene Corporation.  To
read the entire press release, please go to

Derma Sciences Inc. (NASDAQ: DSCI) closed up slightly on Friday July 5th in
light trading. DSCI operates as a medical technology company primarily in the
United States and Canada. It operates in three segments: Advanced Wound Care,
Traditional Wound Care, and Pharmaceutical Wound Care. The company offers
Medihoney dressings for the management of non-chronic and hard-to-heal wounds,
such as chronic ulcers, burns, and post-operative wounds; TCC-EZ dressing
system for the management of diabetic foot ulcers; and Xtrasorb dressings that
convert fluid within the dressings to a gel and lock the exudates into the

MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and
marketer of patent protected regenerative biomaterials and bioimplants
processed from human amniotic membrane, announced recently that it has been
included in the Russell 2000, the Russell 3000 and the Russell Global Indexes
effective at the start of trading on July 1, 2013. Its biomaterial platform
technologies include HydroFix and CollaFix device technologies; and AmnioFix
and EpiFix tissue technologies. Its tissue technologies, processed from the
human amniotic membrane, utilize its proprietary Purion process to produce
minimally manipulated implants. MDXG closed up slightly on Friday on below
average trading volume.

Integra LifeSciences Holdings Corporation (NASDAQ: IART) recently announced
the company will release its second quarter 2013 financial results on
Thursday, August 1, 2013. The company has scheduled a conference call for 8:30
AM ET the same day to discuss the results. Integra's senior management team
will host the conference call, which will be open to all listeners. For
complete details, please visit There will also be
a question and answer session following the prepared remarks. IART develops,
manufactures, and markets surgical implants and medical instruments for
neurosurgery, extremity reconstruction, orthopedics, and general surgery.

Oculus Innovative Sciences, Inc. (NASDAQ: OCLS) a global healthcare company
that designs, manufactures and markets prescription and non-prescription
products in 27 countries, announced the allowance of a Mexican patent for the
use of the company's novel antimicrobial surgical solution in the treatment
and prevention of peritonitis. The imminent issuance of this Mexican patent,
expiring in 2027, provides Oculus' Latin American partner, More Pharma, the
opportunity to pursue a new drug candidate in Latin America in parallel to
Oculus' subsidiary, Ruthigen, Inc.'s, development of the drug for the U.S.
market. The novel new formulation, RUT58-60, is an advanced next-generation
Microcyn Technology drug candidate specifically engineered for use in invasive
surgical procedures, including peritonitis.

FinancialNewsMedia.comis leading provider of third party publishing &news
dissemination services. If you would like more information regarding our news
coverage solutions, please visithttp://www.financialnewsmedia.comfor more
details. Get an edge on the market with ourPremium News Alerts that are
FREE for a limited time at Follow us on

DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news
dissemination service provider, which disseminates electronic information
through multiple online media channels. FNMG is NOT affiliated in any manner
with any company mentioned herein. FNMG and its affiliated companies are a
news dissemination and financial marketing solutions provider and are NOT a
registered broker/dealer/analyst/adviser, holds no investment licenses and may
NOT sell, offer to sell or offer to buy any security. FNMG's market updates,
news alerts and corporate profiles are NOT a solicitation or recommendation to
buy, sell or hold securities. The material in this release is intended to be
strictly informational and is NEVER to be construed or interpreted as research
material. All readers are strongly urged to perform research and due
diligence on their own and consult a licensed financial professional before
considering any level of investing in stocks. The companies that are
discussed in this release may or may not have approved the statements made in
this release. FNMG is not liable for any investment decisions by its readers
or subscribers. Investors are cautioned that they may lose all or a portion
of their investment when investing in stocks.


This release contains "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E the
Securities Exchange Act of 1934, as amended and such forward-looking
statements are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. "Forward-looking statements"
describe future expectations, plans, results, or strategies and are generally
preceded by words such as "may", "future", "plan" or "planned", "will" or
"should", "expected," "anticipates", "draft", "eventually" or "projected". You
are cautioned that such statements are subject to a multitude of risks and
uncertainties that could cause future circumstances, events, or results to
differ materially from those projected in the forward-looking statements,
including the risks that actual results may differ materially from those
projected in the forward-looking statements as a result of various factors,
and other risks identified in a company's annual report on Form 10-K or 10-KSB
and other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue reliance on
such statements. The forward-looking statements in this release are made as of
the date hereof and FNMG undertakes no obligation to update such statements.

Contact Information:
Company: FN Media Group, LLC
Contact email:
U.S. Phone: +1(954)345-0611

Press spacebar to pause and continue. Press esc to stop.